Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Acer MedicalROCO:6857 -1.64%51 EPS without NRI is NT$-1.95 as of Dec. 2025. GuruFocus rates ROCO:6857 with a GF Score™ of 51/100 and a GF Value™ of NT$265.13 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 508 Healthcare Providers & Services companies, Acer Medical ranks better than 65.55% on this metric.
Acer Medical's earnings per share without non-recurring items for the
six
months ended in Dec. 2025 was NT$-0.96.
Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-1.95.
During the past 3 years, the average earnings per share (NRI) Growth Rate was 23.90% per year.
During the past 5 years, the average earnings per share (NRI) Growth Rate was 7.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.
The historical rank and industry rank for Acer Medical's EPS without NRI or its related term are showing as below:
ROCO:6857'
s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -59.7 Med: 4.45 Max: 23.9
Current: 23.9
During the past 7 years, Acer Medical's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 23.90% per year. The lowest was -59.70% per year. And the median was 4.45% per year.
ROCO:6857's 3-Year EPS without NRI Growth Rate is ranked better than 65.55% of 508
companies
in the Healthcare Providers & Services industry
Industry Median: 11.3
vs ROCO:6857: 23.90
Acer Medical's EPS (Diluted) for the
six
months ended in Dec. 2025 was NT$-0.96.
Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-1.95.
Acer Medical's EPS (Basic) for the
six
months ended in Dec. 2025 was NT$-0.96.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-1.95.
Acer Medical (ROCO:6857) EPS without NRI Explanation
EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Acer Medical EPS without NRI Related Terms
Acer Medical EPS without NRI Historical Data
* Premium members only.
The historical data trend for Acer Medical's EPS without NRI can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6857 vs VEEV, BTSG, HQY: EPS without NRI Comparison
For the Health Information Services subindustry, Acer Medical's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acer Medical PE Ratio without NRI vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Acer Medical's PE Ratio without NRI distribution charts can be found below:
* The bar in red indicates where Acer Medical's PE Ratio without NRI falls into.
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.
EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$-1.95
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acer Medical (ROCO:6857) has a EPS without NRI of NT$-1.95 as of Dec. 2025. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Acer Medical and its competitors. According to the industry distribution chart, Acer Medical ranks #175 out of 508 companies in the Healthcare Providers & Services industry, placing it in the top 34.4%.
Is Acer Medical's EPS without NRI too high?
Acer Medical's current EPS without NRI is NT$-1.95. Based on the distribution chart, Acer Medical ranks #175 out of 508 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Acer Medical has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Acer Medical's EPS without NRI compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, Acer Medical ranks #175 out of 508 companies for EPS without NRI. This puts Acer Medical in the upper half of its industry. The industry median EPS without NRI is 11.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS without NRI for a Healthcare Providers & Services company?
The median EPS without NRI among Healthcare Providers & Services companies is 11.30, based on 508 companies in the industry. Companies in the top quartile (top 25%) have a EPS without NRI significantly above this median, while those in the bottom quartile fall well below. However, EPS without NRI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS without NRI mean?
A high EPS without NRI can signal that a stock is expensive relative to its fundamentals. EPS without NRI represents per-share earnings excluding one-time charges. View historical data on Acer Medical and its competitors. For the Healthcare Providers & Services industry, the median EPS without NRI is 11.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Acer Medical's current EPS without NRI is NT$-1.95. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Acer Medical stock overvalued right now?
Based on GuruFocus' analysis, Acer Medical (ROCO:6857) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$265.13, compared to a current price of NT$90.00 — trading 66.1% below its estimated fair value. The current EPS without NRI is NT$-1.95. Acer Medical's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS without NRI calculated?
EPS without NRI is calculated from a company's financial statements. For Acer Medical (ROCO:6857), the current EPS without NRI is NT$-1.95 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Acer Medical (ROCO:6857) Overvalued in 2026?
Based on GuruFocus' analysis, Acer Medical stock appears to be undervalued.
The current stock price of NT$90.00 is trading 66.1% below its estimated GF Value™ of NT$265.13.
GuruFocus considers Acer Medical to be Significantly Undervalued.
Key valuation signals for ROCO:6857:
EPS without NRI: NT$-1.95
GF Value™: NT$265.13 vs. price of NT$90.00 (66.1% below fair value)
No single metric tells the full story. See the ROCO:6857 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Acer Medical Inc focuses on improving human health and well-being through artificial intelligence. It focuses on applying artificial intelligence and large data to the area of healthcare. Acer Medical is capable of designing, developing, commercializing, as well as implementing AI solutions in medical institutions.
51GF Score
Get the complete analysis for ROCO:6857
EPS without NRI is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6857 has been successfully added to your 
